Article info

Download PDFPDF
Letter
Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile: a competing risks analysis provides a full picture of possible treatment effects

Authors

  1. Correspondence to Maja Katharina von Cube, Faculty of Medicine and Medical Center, Institute for Medical Biometry and Statistics, University of Freiburg, Freiburg D-79104, Germany; cube{at}imbi.uni-freiburg.de
View Full Text

Citation

von Cube MK, Schumacher M, Wolkewitz M on behalf of COMBACTE-MAGNET Consortium
Follow-on rifaximin for the prevention of recurrence following standard treatment of infection with Clostridium difficile: a competing risks analysis provides a full picture of possible treatment effects

Publication history

  • Received October 31, 2018
  • Revised December 7, 2018
  • Accepted December 9, 2018
  • First published December 28, 2018.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.